International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.
Journal
The Lancet. Haematology
ISSN: 2352-3026
Titre abrégé: Lancet Haematol
Pays: England
ID NLM: 101643584
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
received:
05
05
2019
revised:
19
07
2019
accepted:
22
07
2019
pubmed:
5
11
2019
medline:
18
12
2019
entrez:
3
11
2019
Statut:
ppublish
Résumé
The WHO classification separates mastocytosis into distinct variants, but prognostication remains a clinical challenge. The aim of this study was to improve prognostication for patients with mastocytosis. We analysed data of the registry of the European Competence Network on Mastocytosis including 1639 patients (age 17-90 years) diagnosed with mastocytosis according to WHO criteria between Jan 12, 1978, and March 16, 2017. Univariate and multivariate analyses with Cox regression were applied to identify prognostic variables predicting survival outcomes and to establish a prognostic score. We validated this International Prognostic Scoring System in Mastocytosis (IPSM) with data of 462 patients (age 17-79 years) from the Spanish network Red Española de Mastocitosis diagnosed between Jan 22, 1998, and Nov 2, 2017. The prognostic value of the WHO classification was confirmed in our study (p<0·0001). For patients with non-advanced mastocytosis (n=1380), we identified age 60 years or older (HR 10·75, 95% CI 5·68-20·32) and a concentration of alkaline phosphatase 100 U/L or higher (2·91, 1·60-5·30) as additional independent prognostic variables for overall survival. The resulting scoring system divided patients with non-advanced mastocytosis into three groups: low (no risk factors), intermediate 1 (one risk factor), and intermediate 2 (two risk factors). Overall survival and progression-free survival differed significantly among these groups (p<0·0001). In patients with advanced mastocytosis (n=259), age 60 years or older (HR 2·14, 95% CI 1·42-3·22), a concentration of tryptase 125 ng/mL or higher (1·81, 1·20-2·75), a leukocyte count of 16 × 10 The IPSM scores for patients with non-advanced and advanced mastocytosis can be used to predict survival outcomes and guide treatment decisions. However, the predictive value of the IPSM needs to be confirmed in forthcoming trials. Austrian Science Fund, Deutsche Forschungsgemeinschaft, Koeln Fortune Program, Charles and Ann Johnson Foundation, Instituto de Salud Carlos III, Fondos FEDER, Research-Foundation Flanders/Fonds Wetenschappelijk Onderzoek, Clinical Research-Fund of the University Hospitals Leuven, and Research-Foundation Flanders/Fonds Wetenschappelijk Onderzoek.
Sections du résumé
BACKGROUND
BACKGROUND
The WHO classification separates mastocytosis into distinct variants, but prognostication remains a clinical challenge. The aim of this study was to improve prognostication for patients with mastocytosis.
METHODS
METHODS
We analysed data of the registry of the European Competence Network on Mastocytosis including 1639 patients (age 17-90 years) diagnosed with mastocytosis according to WHO criteria between Jan 12, 1978, and March 16, 2017. Univariate and multivariate analyses with Cox regression were applied to identify prognostic variables predicting survival outcomes and to establish a prognostic score. We validated this International Prognostic Scoring System in Mastocytosis (IPSM) with data of 462 patients (age 17-79 years) from the Spanish network Red Española de Mastocitosis diagnosed between Jan 22, 1998, and Nov 2, 2017.
FINDINGS
RESULTS
The prognostic value of the WHO classification was confirmed in our study (p<0·0001). For patients with non-advanced mastocytosis (n=1380), we identified age 60 years or older (HR 10·75, 95% CI 5·68-20·32) and a concentration of alkaline phosphatase 100 U/L or higher (2·91, 1·60-5·30) as additional independent prognostic variables for overall survival. The resulting scoring system divided patients with non-advanced mastocytosis into three groups: low (no risk factors), intermediate 1 (one risk factor), and intermediate 2 (two risk factors). Overall survival and progression-free survival differed significantly among these groups (p<0·0001). In patients with advanced mastocytosis (n=259), age 60 years or older (HR 2·14, 95% CI 1·42-3·22), a concentration of tryptase 125 ng/mL or higher (1·81, 1·20-2·75), a leukocyte count of 16 × 10
INTERPRETATION
CONCLUSIONS
The IPSM scores for patients with non-advanced and advanced mastocytosis can be used to predict survival outcomes and guide treatment decisions. However, the predictive value of the IPSM needs to be confirmed in forthcoming trials.
FUNDING
BACKGROUND
Austrian Science Fund, Deutsche Forschungsgemeinschaft, Koeln Fortune Program, Charles and Ann Johnson Foundation, Instituto de Salud Carlos III, Fondos FEDER, Research-Foundation Flanders/Fonds Wetenschappelijk Onderzoek, Clinical Research-Fund of the University Hospitals Leuven, and Research-Foundation Flanders/Fonds Wetenschappelijk Onderzoek.
Identifiants
pubmed: 31676322
pii: S2352-3026(19)30166-8
doi: 10.1016/S2352-3026(19)30166-8
pmc: PMC7115823
mid: EMS87075
pii:
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e638-e649Subventions
Organisme : Austrian Science Fund FWF
ID : F 4701
Pays : Austria
Organisme : Austrian Science Fund FWF
ID : F 4704
Pays : Austria
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.
Références
Leukemia. 2016 Dec;30(12):2342-2350
pubmed: 27416984
Blood. 2015 Aug 20;126(8):1009-16; quiz 1050
pubmed: 26002962
Blood Adv. 2018 Nov 13;2(21):2814-2828
pubmed: 30373888
Eur J Clin Invest. 2007 Jun;37(6):435-53
pubmed: 17537151
Allergy. 2014 Jun;69(6):810-3
pubmed: 24750133
Leukemia. 2016 Jan;30(1):136-43
pubmed: 26464169
Blood. 2017 Jul 13;130(2):137-145
pubmed: 28424161
Blood. 2015 Jul 2;126(1):9-16
pubmed: 25931582
J Allergy Clin Immunol Pract. 2019 Jan;7(1):81-87
pubmed: 30416055
Leuk Res. 2001 Jul;25(7):603-25
pubmed: 11377686
Blood Adv. 2018 Nov 13;2(21):2964-2972
pubmed: 30413432
Leukemia. 2016 Apr;30(4):914-8
pubmed: 26678095
J Leukoc Biol. 2015 Jan;97(1):49-59
pubmed: 25381388
PLoS One. 2008 May 28;3(5):e2266
pubmed: 18509466
Blood Cancer J. 2019 Mar 4;9(3):29
pubmed: 30833549
Int Arch Allergy Immunol. 2002 Jun;128(2):136-41
pubmed: 12065914
Br J Haematol. 2014 Aug;166(4):521-8
pubmed: 24761987
N Engl J Med. 1992 Feb 27;326(9):619-23
pubmed: 1370856
Leuk Res. 2001 Jul;25(7):563-70
pubmed: 11377681
Allergy. 2016 Jun;71(6):869-77
pubmed: 26797792
N Engl J Med. 2016 Jun 30;374(26):2530-41
pubmed: 27355533
Leuk Res. 2001 Jul;25(7):529-36
pubmed: 11377677
Blood. 2013 Oct 3;122(14):2460-6
pubmed: 23958953
Blood. 2017 Mar 16;129(11):1420-1427
pubmed: 28031180
Blood. 2008 Aug 15;112(4):946-56
pubmed: 18684881
Blood. 2017 Jan 19;129(3):371-382
pubmed: 27856463
Annu Rev Med. 2004;55:419-32
pubmed: 14746529
Blood. 2009 Jun 4;113(23):5727-36
pubmed: 19363219
J Clin Oncol. 2014 Oct 10;32(29):3264-74
pubmed: 25154823
J Allergy Clin Immunol. 2009 Sep;124(3):514-21
pubmed: 19541349